These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 25706332)

  • 21. A comparison of characteristics and outcomes of opioid-dependent patients initiating office-based buprenorphine or methadone maintenance treatment.
    Fingerhood MI; King VL; Brooner RK; Rastegar DA
    Subst Abus; 2014; 35(2):122-6. PubMed ID: 24821346
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Medicaid Expansion on Medicaid-covered Utilization of Buprenorphine for Opioid Use Disorder Treatment.
    Wen H; Hockenberry JM; Borders TF; Druss BG
    Med Care; 2017 Apr; 55(4):336-341. PubMed ID: 28296674
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Responses of state Medicaid programs to buprenorphine diversion: doing more harm than good?
    Clark RE; Baxter JD
    JAMA Intern Med; 2013 Sep; 173(17):1571-2. PubMed ID: 23877740
    [No Abstract]   [Full Text] [Related]  

  • 24. Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians.
    DeFlavio JR; Rolin SA; Nordstrom BR; Kazal LA
    Rural Remote Health; 2015; 15():3019. PubMed ID: 25651434
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Unobserved "home" induction onto buprenorphine.
    Lee JD; Vocci F; Fiellin DA
    J Addict Med; 2014; 8(5):299-308. PubMed ID: 25254667
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Physician-pharmacist collaborative care model for buprenorphine-maintained opioid-dependent patients.
    DiPaula BA; Menachery E
    J Am Pharm Assoc (2003); 2015; 55(2):187-92. PubMed ID: 25749264
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Feasibility of Implementing Shared Medical Appointments (SMAs) for Office-Based Opioid Treatment With Buprenorphine: A Pilot Study.
    Suzuki J; Zinser J; Klaiber B; Hannon M; Grassi H; Spinosa M; Ramirez A; Issa M; Chin Feman SP
    Subst Abus; 2015; 36(2):166-9. PubMed ID: 25738320
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia.
    Burns L; Gisev N; Larney S; Dobbins T; Gibson A; Kimber J; Larance B; Mattick RP; Butler T; Degenhardt L
    Addiction; 2015 Apr; 110(4):646-55. PubMed ID: 25516077
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Using Shared Medical Appointments to Increase Access to Buprenorphine Treatment.
    Roll D; Spottswood M; Huang H
    J Am Board Fam Med; 2015; 28(5):676-7. PubMed ID: 26355141
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reimbursement and practice policies among providers of buprenorphine-naloxone treatment.
    Wisniewski AM; Dlugosz MR; Blondell RD
    Subst Abus; 2013; 34(2):105-7. PubMed ID: 23577902
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Beyond health plans: behavioral health disorders and quality of diabetes and asthma care for Medicaid beneficiaries.
    Clark RE; Weir S; Ouellette RA; Zhang J; Baxter JD
    Med Care; 2009 May; 47(5):545-52. PubMed ID: 19319000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Opioid use disorder during pregnancy in Tennessee: expediency vs. science.
    Martin PR; Finlayson AJ
    Am J Drug Alcohol Abuse; 2015; 41(5):367-70. PubMed ID: 26186388
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Medicaid Managed Care: Access To Primary Care Providers Who Prescribe Buprenorphine.
    Meiselbach MK; Drake C; Saloner B; Zhu JM; Stein BD; Polsky D
    Health Aff (Millwood); 2022 Jun; 41(6):901-910. PubMed ID: 35666962
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Receipt of opioid agonist treatment in the Veterans Health Administration: facility and patient factors.
    Oliva EM; Harris AH; Trafton JA; Gordon AJ
    Drug Alcohol Depend; 2012 May; 122(3):241-6. PubMed ID: 22115887
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association between trajectories of buprenorphine treatment and emergency department and in-patient utilization.
    Lo-Ciganic WH; Gellad WF; Gordon AJ; Cochran G; Zemaitis MA; Cathers T; Kelley D; Donohue JM
    Addiction; 2016 May; 111(5):892-902. PubMed ID: 26662858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Description and outcomes of a buprenorphine maintenance treatment program integrated within Prevention Point Philadelphia, an urban syringe exchange program.
    Bachhuber MA; Thompson C; Prybylowski A; Benitez J; Mazzella S; Barclay D
    Subst Abus; 2018; 39(2):167-172. PubMed ID: 29474119
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Geographic and specialty distribution of US physicians trained to treat opioid use disorder.
    Rosenblatt RA; Andrilla CH; Catlin M; Larson EH
    Ann Fam Med; 2015; 13(1):23-6. PubMed ID: 25583888
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Methadone versus buprenorphine for the treatment of opioid abuse in pregnancy: science and stigma.
    Holbrook AM
    Am J Drug Alcohol Abuse; 2015; 41(5):371-3. PubMed ID: 26154531
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary care patient characteristics associated with completion of 6-month buprenorphine treatment.
    Neumann AM; Blondell RD; Azadfard M; Nathan G; Homish GG
    Addict Behav; 2013 Nov; 38(11):2724-8. PubMed ID: 23934003
    [TBL] [Abstract][Full Text] [Related]  

  • 40. State Policy and the Breadth of Buprenorphine-Prescriber Networks in Medicaid Managed Care.
    Meiselbach MK; Drake C; Zhu JM; Manibusan B; Nagy D; Sorbero MJ; Saloner B; Stein BD; Polsky D
    Med Care Res Rev; 2023 Aug; 80(4):423-432. PubMed ID: 37083043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.